Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis
E Byun, SJ Caillier, X Montalban… - Archives of …, 2008 - jamanetwork.com
Objective To identify promising candidate genes linked to interindividual differences in the
efficacy of interferon beta therapy. Recombinant interferon beta therapy is widely used to
reduce disease activity in multiple sclerosis (MS). However, up to 50% of patients continue
to have relapses and worsening disability despite therapy. Design We used a genome-wide
pharmacogenomic approach to identify single-nucleotide polymorphism (SNP) allelic
differences associated with interferon beta therapy response. Setting Four collaborating …
efficacy of interferon beta therapy. Recombinant interferon beta therapy is widely used to
reduce disease activity in multiple sclerosis (MS). However, up to 50% of patients continue
to have relapses and worsening disability despite therapy. Design We used a genome-wide
pharmacogenomic approach to identify single-nucleotide polymorphism (SNP) allelic
differences associated with interferon beta therapy response. Setting Four collaborating …